NASDAQ:AVTX

Avalo Therapeutics - AVTX News Headlines

$5.36

-0.42 (-7.27%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.12
▼
$5.66
50-Day Range: $3.50
▼
$62.16
52-Week Range: $2.42
▼
$38.88

Volume: 52,638 shs
Average Volume: 49,702 shs
Market Capitalization: $50.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Get Avalo Therapeutics News Delivered to You Automatically

AVTX Media Mentions By Week

AVTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AVTX
News Sentiment
▼
0.95

0.63
▲
Average
Medical
News Sentiment

AVTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AVTX Articles
This Week
▼
16

1
▲
AVTX Articles
Average Week

Source

Source	Headline
	Q3 2022 EPS Estimates for Avalo Therapeutics, Inc. Lifted by Analyst (NASDAQ:AVTX) americanbankingnews.com - August 12 at 3:24 AM
	Avalo Therapeutics, Inc. (NASDAQ:AVTX) Forecasted to Post Q3 2022 Earnings of ($1.03) Per Share americanbankingnews.com - August 12 at 2:47 AM
	Avalo Therapeutics Announces Board Changes finance.yahoo.com - August 11 at 8:38 PM
	Wall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know finance.yahoo.com - August 10 at 4:58 PM
	Avalo Therapeutics, Inc. Forecasted to Earn Q1 2023 Earnings of ($0.95) Per Share (NASDAQ:AVTX) americanbankingnews.com - August 9 at 6:52 AM
	Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates finance.yahoo.com - August 4 at 10:59 AM
	Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates finance.yahoo.com - August 4 at 10:59 AM
	Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007 seekingalpha.com - August 2 at 8:47 PM
	Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) finance.yahoo.com - August 2 at 10:46 AM
	Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Growth in Short Interest americanbankingnews.com - August 2 at 3:52 AM
	Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics finance.yahoo.com - August 1 at 8:43 AM

	Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics finance.yahoo.com - August 1 at 8:43 AM
	Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split finance.yahoo.com - July 6 at 5:45 PM
	Investors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years finance.yahoo.com - June 20 at 5:15 PM
	Avalo to Present at the 2022 Jefferies Healthcare Conference finance.yahoo.com - June 2 at 10:44 AM
	Avalo begins dosing in mid-stage study of AVTX-002 for non-eosinophilic asthma seekingalpha.com - May 18 at 5:32 PM
	Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA) finance.yahoo.com - May 18 at 8:56 AM
	Avalo to Present at the H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - May 17 at 8:30 AM
	Avalo Therapeutics vs. Bitcoin: Price Relationship Crosses Threshold nasdaq.com - May 16 at 5:29 PM
	Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates benzinga.com - May 5 at 10:29 AM
	Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates finance.yahoo.com - May 5 at 10:29 AM
	Avalo Therapeutics Inc. barrons.com - April 8 at 4:15 AM
	Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference finance.yahoo.com - March 8 at 11:51 AM
	RBC Capital Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $4 benzinga.com - March 3 at 3:27 PM
	Avalo Therapeutics GAAP EPS of -$0.83 in-line, revenue of $5.4M misses by $0.68M seekingalpha.com - March 2 at 8:35 AM
	Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates apnews.com - March 2 at 8:35 AM
	Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates finance.yahoo.com - March 2 at 8:35 AM
	Avalo Therapeutics picks internal candidate for CEO and CFO role seekingalpha.com - February 17 at 10:28 AM
	Avalo Therapeutics Announces Leadership Transition finance.yahoo.com - February 17 at 10:28 AM
	Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference finance.yahoo.com - February 7 at 6:50 PM
	Avalo Therapeutics, Inc. Common Stock (AVTX) nasdaq.com - January 26 at 12:58 AM
	New commercial chief at Avalo Therapeutics seekingalpha.com - January 11 at 9:27 AM
	Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer finance.yahoo.com - January 10 at 11:26 PM
	Avalo Therapeutics Inc Shares Close the Day 31.3% Lower - Daily Wrap nasdaq.com - January 7 at 10:43 AM

	Avalo Therapeutics Shares Drop 23% After Data for Crohn's, Melanoma Treatments marketwatch.com - January 6 at 2:06 PM
	Avalo Therapeutics discontinues multiple myeloma program; stock plunges 23% seekingalpha.com - January 6 at 2:06 PM
	Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event finance.yahoo.com - January 6 at 9:06 AM
	Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022 finance.yahoo.com - December 16 at 9:46 AM
	Avalo Appoints Two New Independent Directors to Its Board finance.yahoo.com - December 6 at 8:49 AM
	What Type Of Shareholders Make Up Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) Share Registry? finance.yahoo.com - December 5 at 9:39 AM
	Do Options Traders Know Something About Avalo (AVTX) Stock We Don't? nasdaq.com - November 17 at 2:31 PM
	Avalo to Present at Two Upcoming Conferences finance.yahoo.com - November 11 at 9:12 AM
	Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates finance.yahoo.com - November 9 at 8:17 PM
	Avalo Therapeutics, Inc. (AVTX) finance.yahoo.com - November 7 at 12:24 AM
	Avalo Therapeutics (NASDAQ:AVTX) shareholders have endured a 47% loss from investing in the stock three years ago nasdaq.com - November 5 at 9:38 AM
	Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference finance.yahoo.com - September 20 at 7:58 AM
	Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares finance.yahoo.com - September 17 at 3:01 PM
	AVTX.OQ - Avalo Therapeutics Inc Profile \| Reuters reuters.com - September 17 at 8:39 AM
	Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock finance.yahoo.com - September 14 at 11:01 PM
	Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock finance.yahoo.com - September 14 at 6:01 PM

Get Avalo Therapeutics News Delivered to You Automatically

This page (NASDAQ:AVTX) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms